SCHEMBL4715544

SCHEMBL4715544

CCOC(=O)c1cc2c(ccc[n+]2[O-])n1Cc1ccc(F)c(C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD2 Q9HC29 2/20 0.48
NOD1 Q9Y239 2/20 0.48
MAPT P10636 9/20 0.47
TDP1 Q9NUW8 5/20 0.47
KDM4E B2RXH2 5/20 0.47
NPSR1 Q6W5P4 2/20 0.47
MAPK1 P28482 2/20 0.47
ALDH1A1 P00352 4/20 0.45
POLB P06746 2/20 0.45
HTT P42858 1/20 0.45
F10 P00742 4/20 0.44
TSHR P16473 3/20 0.42
ATM Q13315 1/20 0.42
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714912 0.90 MAPT (0.50) NOD2NOD1MAPTTDP1KDM4E
SCHEMBL4713887 0.85 MAPT (0.57) NOD2NOD1MAPTTDP1KDM4E
SCHEMBL4717021 0.85 MAPT (0.50) NOD2NOD1MAPTTDP1KDM4E
SCHEMBL4714613 0.85 NOD2 (0.51) NOD2NOD1MAPTTDP1KDM4E
SCHEMBL4716980 0.78 NOD2 (0.50) NOD2NOD1MAPTTDP1KDM4E
SCHEMBL4715660 0.75 MAPT (0.48) NOD2NOD1MAPTTDP1KDM4E
SCHEMBL4716178 0.73 MAPT (0.47) NOD2NOD1MAPTTDP1KDM4E
SCHEMBL4715422 0.73 MAPT (0.48) NOD2NOD1MAPTTDP1KDM4E
SCHEMBL6706704 0.69 NOD2 (0.82) NOD2NOD1MAPTTDP1KDM4E
SCHEMBL6303484 0.68 CCR2 (0.72) NOD2NOD1MAPTTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed
EP-1549648-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS Celltech R & D Limited (GB) 2005-07-06 EP disclosed
WO-2004031188-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 NOD2 138/4885NOD1 312/4885MAPT 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.